Mutational activation of BRAF contributes to constitutive activation of NF-κB, the key transcriptional factor that controls the production of many cytokines, including IL-1β, and is usually activated by chemotherapy and in cancer drug resistance [24,25,26]. Here, NFKB1 is linked to cancer.